11.15.19
Two double-blind, placebo-controlled human clinical trials indicated AstaZine astaxanthin from Algae Health Sciences, a division of BGG, offered benefits for several markers of mental health and memory, respectively.
In the first study (conducted in the U.S.), researchers found significant improvements in three critical markers including feelings of depression, mental fatigue, and overall mood state [psychological well-being] after 8 weeks in healthy subjects aged 26 to 63 years (median age = 42) taking AstaZine (Talbott, EC Nutrition, 2019). In addition, trends toward improvement in other important mental health parameters such as tension, anger and mental confusion were found through AstaZine supplementation.
The second study (conducted in Japan) looked at very different yet crucial aspects of brain health. The subjects in this study were healthy adults who were experiencing mild forgetfulness. After 12 weeks taking AstaZine, the treatment group showed a statistically significant improvement versus placebo on two tests for cognitive function and memory. Both verbal and composite memory significantly improved as tested by Cognitrax (a computerized testing system used to monitor and measure brain performance). In addition, subjective assessment of symptoms such as remembering people’s names and the names of things were judged by the AstaZine group as having significantly improved (Sekikawa, Pharmacometrics, 2019).
“We’re extremely pleased to have two additional successful clinical trials for AstaZine under our belt,” said Yanmei Li, PhD, chief scientific officer of BGG. “Our goal is to maintain a leadership role in the botanical sector through innovation and continuing scientific discoveries.”
In the first study (conducted in the U.S.), researchers found significant improvements in three critical markers including feelings of depression, mental fatigue, and overall mood state [psychological well-being] after 8 weeks in healthy subjects aged 26 to 63 years (median age = 42) taking AstaZine (Talbott, EC Nutrition, 2019). In addition, trends toward improvement in other important mental health parameters such as tension, anger and mental confusion were found through AstaZine supplementation.
The second study (conducted in Japan) looked at very different yet crucial aspects of brain health. The subjects in this study were healthy adults who were experiencing mild forgetfulness. After 12 weeks taking AstaZine, the treatment group showed a statistically significant improvement versus placebo on two tests for cognitive function and memory. Both verbal and composite memory significantly improved as tested by Cognitrax (a computerized testing system used to monitor and measure brain performance). In addition, subjective assessment of symptoms such as remembering people’s names and the names of things were judged by the AstaZine group as having significantly improved (Sekikawa, Pharmacometrics, 2019).
“We’re extremely pleased to have two additional successful clinical trials for AstaZine under our belt,” said Yanmei Li, PhD, chief scientific officer of BGG. “Our goal is to maintain a leadership role in the botanical sector through innovation and continuing scientific discoveries.”
